Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K3 | Q8IVH8 | 3/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.45 |
| ▸ | MET | P08581 | 3/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | SIK1 | P57059 | 1/20 | 0.44 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321067 | 0.93 | INPPL1 (0.50) | MAP4K3ALKMETPIM1CHRNB2 | |
| Hydrochloric Acid SCHEMBL2324061 | 0.93 | INPPL1 (0.49) | MAP4K3ALKMETPIM1CHRNB2 | |
| SCHEMBL2320474 | 0.92 | MAP4K1 (0.53) | MAP4K3ALKMETPIM1CHRNB2 | |
| Hydrochloric Acid SCHEMBL13834975 | 0.91 | MAP4K1 (0.52) | MAP4K3ALKMETPIM1CHRNB2 | |
| SCHEMBL2324969 | 0.90 | MET (0.44) | MAP4K3ALKMETPIM1MAP4K1 | |
| SCHEMBL12440741 | 0.90 | PIM1 (0.42) | MAP4K3ALKMETPIM1MAP4K1 | |
| Hydrochloric Acid SCHEMBL2325279 | 0.90 | MET (0.43) | MAP4K3ALKMETPIM1MAP4K1 | |
| SCHEMBL12439733 | 0.89 | MET (0.46) | MAP4K3NTRK1MET | |
| SCHEMBL12440059 | 0.86 | MET (0.45) | NTRK1MET | |
| SCHEMBL13834364 | 0.84 | FGFR1 (0.44) | NTRK1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531500-B1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| EP-2531500-B1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8614226-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| EP-2531500-A1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2011095196-A1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095196-A1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | MAP4K3 3231/4885NTRK1 4085/4885ALK 3020/4885 |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | MAP4K3 3231/4885NTRK1 4085/4885ALK 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.